Can a simple health quiz predict chemo risks in seniors with myeloma?
NCT ID NCT05918185
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 56 older adults (65+) with multiple myeloma to see if a comprehensive geriatric assessment—a series of questions and tests about physical and mental health—along with blood tests could predict who would have serious side effects from chemotherapy. The goal is to help doctors tailor treatments to each patient's fitness level. The study did not test a new treatment but gathered information to improve future care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
56 people
The number who actually took part.
- Started
-
Feb 2023
- Finished
-
Aug 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients over the age of 65 planned to start a new treatment for MM at Mayo Clinic in Rochester.
- Ages
-
65 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age \>= 65 years * Diagnosis of MM based on International Myeloma Working Group (IMWG) diagnostic criteria * Newly diagnosed or have received 1 prior line of treatment * Planned to start a new treatment for MM within 30 days * Transplant eligible or ineligible * Fluent in English (all assessment tools are in English) * Able to provide written informed consent Exclusion Criteria: * Received \> 1 prior line of treatment * Patients included in an interventional therapeutic trial * Not able to give informed consent * Severe mental or cognitive disorder precluding geriatric assessment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Plasma cell myeloma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells target CS1 to fight stubborn myeloma
- Can a cancer drug's real-world performance match clinical trial results?
- Can a maintenance drug keep myeloma at bay?
- New hope for frail myeloma patients: phase III trial tests smarter drug combos
- Could a tiny dose of radiation ease myeloma bone pain?
- Could a common allergy pill ease bone pain in myeloma treatment?